The objective of Phenomix Sciences, LLC (Phenomix) is to provide healthcare solutions that enable personalized management of chronic diseases with better efficacy, fewer side effects, and lower costs. Our approach is based on a phenotype-driven multi-level “omics” platform supported with deep learning technology to identify chronic disease sub-types in order to individualize therapy selection and enhance treatment outcomes. Our first product tackles obesity with a novel blood-based test that is designed to accurately predict the subtype of obesity with a sensitivity and specificity >90%. This innovative test helps guide the health care provider to select the optimal intervention for each patient to help maximize weight loss. In two randomized trials performed within a multidisciplinary weight management clinic, the Phenomix approach demonstrated a doubling of total body weight loss and reduction in side effects to obesity pharmacotherapy. This test will be the first of its kind offered to clinicians and patients to help predict weight loss and improve outcome in obesity.